The new patent for neflamapimod covers the treatment of dementia with Lewy bodies in patients without significant signs of Alzheimer’s disease.

View CervoMed Inc. CRVO stock quote prices, financial information, real-time forecasts, and company news from CNN.

AI checks found a distorted shadow on the guard's uniform and blurry name tags, signs of possible AI-generated visuals ...

The company could receive an additional $21.7 million if all warrants are exercised. The financing is expected to extend CervoMed's cash runway into the second quarter of 2027. CervoMed also plans to ...

Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain ...

On June 22, 2026, CervoMed Inc. closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising gross proceeds of $10 million before fees and expenses. H.C.

In a report released today, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on CervoMed, with a price target of $9.00. Introducing TipRanks MCP for Agents. Deliver ins ...

A purported courtroom photograph of former Pakistan Prime Minister Imran Khan has gone viral on social media, with many of ...

CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of ...

CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has entered into ...